China Securities Intelligent Finance - China Pharmaceutical(600056) announced on March 6 that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., recently received two "Approval Notices for Supplementary Applications" for minoxidil liniment issued by the National Medical Products Administration, becoming the marketing authorization holder for the drug.

The announcement indicates that minoxidil topical solution is a dermatology and ENT medication used to treat male pattern baldness and alopecia areata. The National Medical Products Administration (NMPA) accepted a supplementary application for a change of marketing authorization holder for this drug in January 2026, and the project has accumulated an investment of approximately 6.45 million yuan as of the date of this announcement.

According to the third-party database Menet, the drug's sales in China's three major terminals and six major markets reached approximately 447 million yuan in 2024, and approximately 315 million yuan in the first three quarters of 2025.

The company stated that this approval will further enrich its product line and help enhance its market competitiveness.

https://finance.eastmoney.com/a/202603063664062993.html